The XBB.1.5 mRNA booster vaccine does not significantly increase the percentage of XBB.1.5 mono-reactive T cells
Open Access
- 12 March 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1513175
Abstract
Recent efforts in vaccine development have targeted spike proteins from evolving SARS-CoV-2 variants. In this study, we analyzed T cell responses to the XBB.1.5 and BA.2.86 subvariants in individuals who previously received bivalent vaccines containing mRNA for ancestral and BA.5 spike proteins. T cell-mediated cytokine responses to spike proteins from both variants were largely preserved. To determine the mechanism of this preserved recognition, we utilized the functional expansion of specific T cells (FEST) assay to distinguish between the presence of T cells that cross-recognized ancestral and variant epitopes versus distinct populations of T cells that were mono-reactive for ancestral or variant epitopes. We found the majority of spike-specific T cells cross-recognized the ancestral spike and the XBB.1.5 and BA.2.86 subvariants, with less than 10% of T cells being mono-reactive for either variant. Interestingly, immunization with the XBB.1.5 monovalent booster vaccine did not significantly increase the percentage of XBB.1.5 mono-reactive T cells. Our results suggest a potential limitation in the induction of mono-reactive T cell responses by variant-specific booster vaccines.Keywords
Funding Information
- National Institutes of Health
This publication has 50 references indexed in Scilit:
- JN.1 neutralizing antibody titers after XBB.1.5 monovalent vaccine boost in healthcare workers and people with HIVJournal of Medical Virology, 2024
- Sixth monovalent XBB.1.5 vaccine elicits robust immune response against emerging SARS-CoV-2 variants in heart transplant recipientsThe Journal of Heart and Lung Transplantation, 2024
- XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1Cell Host & Microbe, 2024
- Post-pandemic memory T cell response to SARS-CoV-2 is durable, broadly targeted, and cross-reactive to the hypermutated BA.2.86 variantCell Host & Microbe, 2024
- Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variantCell Host & Microbe, 2024
- Pre-existing SARS-2-specific T cells are predicted to cross-recognize BA.2.86Cell Host & Microbe, 2023
- Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariantsCell, 2022
- SARS-CoV-2 vaccination diversifies the CD4+ spike-reactive T cell repertoire in patients with prior SARS-CoV-2 infectionEBioMedicine, 2022
- SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19Cell Host & Microbe, 2021
- Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19Immunity, 2020